Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
Budget negotiation success hinges on clear communication and early resource sharing, helping sites and sponsors align expectations and avoid costly delays.
Medicare Coverage Analysis outlines criteria to determine coverage eligibility, guiding trials through compliance with CMS guidelines for billable services.
Antibiotic resistance is an emerging problem. Some have argued bacteria are developing antibiotic resistance faster than we can research, develop,
A regulatory binder is essential for managing clinical trial documents, ensuring regulatory compliance, and facilitating audits. It organizes critical documents;
Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their
Training is crucial for changing employee behavior, but not every issue requires it. Identifying when training is necessary can enhance effectiveness and accountability.
Maintaining complete and compliant documentation while managing the complex processes and interactions of clinical trial conduct can be complicated. This blog outlines the details to look out for preparing your investigator site file (ISF) for an audit.
The only constant in clinical research is change. Researchers are always innovating, making it a necessity to navigate complex organizational
Interim staffing offers HRPPs specialized expertise, fresh perspectives, and support for accreditation and structural improvements without disrupting daily operations.
The FDA’s 2024 draft guidance emphasizes the critical role of independent DMCs in clinical trials, enhancing oversight, safety, and trial integrity.
